Damora Therapeutics Inc. Ordinary Shares (DMRA)
Stock · NASDAQ · Health Care
$18.44as of 10/16/2026
Price chart
Active signals
DMRA Signal Track Record
How signals performed across all stocks →What DMRA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 26 | -2.4% | 38% | September 25, 2026 |
| Bollinger Band Breakout | 23 | -11.7% | 30% | August 19, 2026 |
| Bollinger Band Breakdown | 20 | -5.2% | 35% | September 15, 2026 |
| 200-Day Moving Average TouchActive now | 9 | 0.0% | 44% | September 9, 2026 |
| Any 20-session window (baseline) | -1.4% | 46% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About DMRA
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 7
- Website
- galecto.com/
Fundamentals
- 1-day range
- $18.5$20.28
- Market cap
- $1.84B
- P/E (trailing)
- —
- P/E (forward)
- -8.54
- EPS (trailing)
- $-139.34
- Dividend yield
- —
- Beta
- -3.96
- Avg. volume
- 532.8K
Forecasts
9 analyst ratings
Damora Therapeutics Inc. Ordinary Shares Competitors
Chosen by industry and closest market cap.
- DMRADamora Therapeutics Inc. Ordinary Shares$18.44▼ 1.60%Market cap $1.84BP/E —$16.5$34.89
- NBTXNanobiotix S.A. American Depositary Shares$21.3▼ 4.18%Market cap $1.83BP/E —$13.1$47.66
- CMPSCOMPASS Pathways Plc American Depository Shares$10.75▼ 7.49%Market cap $1.83BP/E —$4.88$15.87
- ANIPANI Pharmaceuticals Inc.$72.29▲ 0.01%Market cap $1.86BP/E 15.16$69.58$97
- NAMSWNewAmsterdam Pharma Company N.V. Warrant$9▼ 17.81%Market cap $1.87BP/E —$9.79$30.45
- BCAXBicara Therapeutics Inc. Common Stock$16.78▼ 4.77%Market cap $1.81BP/E —$13.7$30.99
- KARDKardigan Inc. Common Stock$13.03▼ 6.12%Market cap $1.79BP/E —$12.23$27
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| DMRA Damora Therapeutics Inc. Ordinary Shares | $1.84B | — | $18.44 | ▼ 1.60% | $16.5$34.89 |
| NBTX Nanobiotix S.A. American Depositary Shares | $1.83B | — | $21.3 | ▼ 4.18% | $13.1$47.66 |
| CMPS COMPASS Pathways Plc American Depository Shares | $1.83B | — | $10.75 | ▼ 7.49% | $4.88$15.87 |
| ANIP ANI Pharmaceuticals Inc. | $1.86B | 15.16 | $72.29 | ▲ 0.01% | $69.58$97 |
| NAMSW NewAmsterdam Pharma Company N.V. Warrant | $1.87B | — | $9 | ▼ 17.81% | $9.79$30.45 |
| BCAX Bicara Therapeutics Inc. Common Stock | $1.81B | — | $16.78 | ▼ 4.77% | $13.7$30.99 |
| KARD Kardigan Inc. Common Stock | $1.79B | — | $13.03 | ▼ 6.12% | $12.23$27 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Damora Therapeutics (DMRA) Stock Looks Above Fair Value On Book ValueYahoo · 10/10/2026
- Damora Therapeutics (DMRA) Climbed, So What Is Drawing Attention Now?Yahoo · 10/10/2026
- Wedbush Reiterates Outperform on Damora Therapeutics, Maintains $40 Price TargetBenzinga · 9/29/2026
- Guggenheim Maintains Buy on Damora Therapeutics, Raises Price Target to $60Benzinga · 9/25/2026
- Damora Therapeutics: Potential Payday Is A Long Way OffSeekingAlpha · 9/15/2026
Insider Activity
Insider Actions →- Jennifer Jarrett · September 25, 2026 · Buy12.5K @ $20.23
- Cheng Andrew · August 12, 2026 · Grant30.4K
- Winslow Garrett · July 6, 2026 · Sale245 @ $29.98
- Winslow Garrett · July 3, 2026 · Option Exercise680
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
DMRA Shares Rise Amid Valuation Debate
Damora Therapeutics shares have climbed recently, drawing attention to potential overvaluation relative to book value. While the stock is trading near its 52-week low, analyst targets remain significantly higher than the current price. This divergence highlights a split between short-term technical weakness and long-term fundamental expectations.
DMRA Shares Rise Amid Valuation Debate. Damora Therapeutics shares have climbed recently, drawing attention to potential overvaluation relative to book value. While the stock is trading near its 52-week low, analyst targets remain significantly higher than the current price. This divergence highlights a split between short-term technical weakness and long-term fundamental expectations.